Gyre Therapeutics (GYRE) Exchange Rate Effect (2023 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Exchange Rate Effect of $285000.0 for Q1 2026, up 470.0% year-over-year from $50000.0 in Q1 2025, and up 124.41% quarter-over-quarter from $127000.0 in Q4 2025.
Powered by 
Analysis
Gyre Therapeutics (GYRE) Exchange Rate Effect (2023 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Exchange Rate Effect for 4 consecutive years, with $285000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Exchange Rate Effect rose 470.0% year-over-year to $285000.0; the TTM figure through Mar 2026 stood at $578000.0 (up 426.55% YoY), while the FY2025 annual figure was $343000.0, up 225.64% from the prior year.
- Exchange Rate Effect advanced to $285000.0 in Q1 2026 per GYRE's latest filing, from $127000.0 in the prior quarter.
- Across five years, Exchange Rate Effect topped out at $285000.0 in Q1 2026 and bottomed at -$900000.0 in Q2 2023.
- Historically, Exchange Rate Effect has averaged $4384.6 across 4 years, with a median of $106000.0 in 2024.
- Annual changes were most pronounced in 2024 — Exchange Rate Effect plunged 210.39% — and 2026, when it soared 470.0%.
- Gyre Therapeutics' Exchange Rate Effect stood at $231000.0 in 2023, then slumped by 210.39% to -$255000.0 in 2024, then jumped by 149.8% to $127000.0 in 2025, then jumped by 124.41% to $285000.0 in 2026.
- Business Quant data shows GYRE's Exchange Rate Effect at $285000.0 in Q1 2026, $127000.0 in Q4 2025, and $117000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -2.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.84 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -287,000.00 |
| 10 | Gyre Therapeutics | 691.38 Mn | 633.98 Mn | 26.90 Mn | 643,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 643,000.00 |
| Mar 31, 2026 | 285,000.00 |
| Dec 31, 2025 | 127,000.00 |
| Sep 30, 2025 | 206,000.00 |
| Jun 30, 2025 | -40,000.00 |
| Mar 31, 2025 | 50,000.00 |
| Dec 31, 2024 | -255,000.00 |
| Sep 30, 2024 | 106,000.00 |
| Jun 30, 2024 | -78,000.00 |
| Mar 31, 2024 | -46,000.00 |
| Dec 31, 2023 | 231,000.00 |
| Sep 30, 2023 | 171,000.00 |
| Jun 30, 2023 | -900,000.00 |
| Mar 31, 2023 | 200,000.00 |